| 5.93 0.04 (0.68%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.41 | 1-year : | 9.55 |
| Resists | First : | 7.2 | Second : | 8.18 |
| Pivot price | 6.12  |
|||
| Supports | First : | 5.63 | Second : | 4.68 |
| MAs | MA(5) : | 5.85 |
MA(20) : | 6.33 |
| MA(100) : | 7.13 |
MA(250) : | 9.72 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 13.5 |
| RSI | RSI(14): 38.5 |
|||
| 52-week | High : | 29.7 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADVM ] has closed above bottom band by 35.0%. Bollinger Bands are 18.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.08 - 6.1 | 6.1 - 6.13 |
| Low: | 5.66 - 5.69 | 5.69 - 5.71 |
| Close: | 5.89 - 5.93 | 5.93 - 5.97 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Wed, 11 Dec 2024
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Fri, 06 Dec 2024
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 06 Dec 2024
Adverum Awards Key Talent Inducement Grants, Strengthens Team with Strategic Equity Package - StockTitan
Wed, 20 Nov 2024
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 20 Nov 2024
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Fri, 15 Nov 2024
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.259e+007 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 1,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.902e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 922 % |
| Return on Equity (ttm) | -29.9 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -75.51 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 0.86 |
| Dividend | 0 |
| Forward Dividend | 1.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|